AIM
BMRN icon

Allen Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Allen Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,154
Closed -$209K – 162
2018
Q3 		$209K Hold
2,154
– – 0.01% 181
2018
Q2 		$203K Buy
+2,154
New +$189K 0.01% 175

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allen Investment Management's BMRN Position: Q4 2018 in Review

Allen Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 2,154 shares — an estimated $209K sold.

Allen Investment Management first reported a position in BMRN in Q2 2018 and held it in 2 quarters. The position peaked at $209K in Q3 2018. 473 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

  • Allen Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Allen Investment Management sold 2,154 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $209K.
  • Allen Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Allen Investment Management's BioMarin Pharmaceuticals position peaked at $209K in Q3 2018.
  • 473 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Allen Investment Management's 13F filing for Q4 2018, filed 5 Feb 2019.